QURE UNIQURE NV

uniQure to Participate in Multiple Upcoming Industry Conferences in October

uniQure to Participate in Multiple Upcoming Industry Conferences in October

LEXINGTON, Mass. and AMSTERDAM, Sept. 30, 2020 (GLOBE NEWSWIRE) -- (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that Matt Kapusta, chief executive officer at uniQure, Maria Cantor, chief communications officer, and Chiara Russo, associate director of investor relations and communications, will participate in the following upcoming conferences in October:

  • SVB Leerink CybeRx Series: Rare & Genetics, October 1, 2020



    • Members of uniQure’s management team will participate in virtual one-on-one investor meetings in the afternoon on Thursday, October 1, 2020.



  • Jefferies Virtual Gene Therapy/Editing Summit, October 1 – 2, 2020



    • A fireside chat with research analyst Suji Jeong, Ph.D. will take place on Friday, October 2, 2020 from 9:00 – 9:25 a.m. ET. The live webcast of the chat can be accessed through the link displayed in the of the uniQure website. The webcast replay will be available for at least 72 hours following the live event.



    • Members of uniQure’s management team will participate in virtual one-on-one investor meetings throughout the morning on Friday, October 2, 2020.



  • Chardan Virtual 4th Annual Genetic Medicines Conference, October 5 – 6, 2020



    • A fireside chat with research analyst Gbola Amusa will take place on Tuesday, October 6, 2020 from 1:00 – 1:25 p.m. ET. The live webcast of the chat can be accessed through the link displayed in the of the uniQure website. The webcast replay will be available for at least 72 hours following the live event.



    • Members of uniQure’s management team will participate in virtual one-on-one investor meetings throughout the afternoon on Tuesday, October 6, 2020.

About uniQure

uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a of proprietary gene therapies to treat patients with hemophilia B, Huntington's disease, Fabry disease, spinocerebellar ataxia Type 3 and other diseases. 

uniQure Contacts:
   
FOR INVESTORS: FOR MEDIA:
   
Maria E. CantorChiara RussoTom Malone
Direct: 339-970-7536Direct: 617-306-9137Direct: 339-970-7558
  



EN
30/09/2020

Underlying

QUREUNIQURE NV

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on UNIQURE NV

 PRESS RELEASE
Free
QURE UNIQURE NV

uniQure Provides Regulatory Update on AMT-130 for Huntington’s Disease

uniQure Provides Regulatory Update on AMT-130 for Huntington’s Disease LEXINGTON, Mass. and AMSTERDAM, Dec. 04, 2025 (GLOBE NEWSWIRE) -- N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the company received final meeting minutes from the U.S. Food and Drug Administration (FDA) regarding a pre-Biologics License Application (BLA) meeting held on October 29, 2025 to discuss the application for AMT-130, an investigational gene therapy for Huntington’s disease (HD).   In the final meeting minu...

December 4, 2025 1 EN
Free Trial
QURE UNIQURE NV

Uniqure Nv: 1 director

A director at Uniqure Nv sold/sold after exercising options 31,434 shares at 27.260USD and the significance rating of the trade was 62/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over t...

11/11/25 November 11, 2025 1 EN
 PRESS RELEASE
Free
QURE UNIQURE NV

uniQure Announces Third Quarter 2025 Financial Results and Provides Co...

uniQure Announces Third Quarter 2025 Financial Results and Provides Corporate Update ~ Announced pivotal topline data from Phase I/II study of AMT-130 in Huntington’s disease met its primary and key secondary endpoints, demonstrating statistically significant slowing of disease progression at 36 months and supportive trends across key clinical and biomarker endpoints ~ ~ Preliminary feedback from FDA at a recent pre-Biologics License Application (BLA) meeting for AMT-130 indicated a key shift from prior regulatory communications; uniQure plans to urgently interact with the FDA to define ne...

November 10, 2025 1 EN
 PRESS RELEASE
Free
QURE UNIQURE NV

uniQure to Announce Third Quarter 2025 Financial Results

uniQure to Announce Third Quarter 2025 Financial Results ~ uniQure to host earnings call on Monday, November 10, 2025 at 8:30 a.m. ET ~ LEXINGTON, Mass. and AMSTERDAM, Nov. 06, 2025 (GLOBE NEWSWIRE) -- N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs will report third quarter 2025 financial results before market open on Monday, November 10, 2025. Management will then host a conference call at 8:30 a.m. ET. The event will be webcast under the Events & Presentations section of uniQure’s website at , and followi...

November 6, 2025 1 EN
 PRESS RELEASE
Free
QURE UNIQURE NV

uniQure Provides Regulatory Update on AMT-130 for Huntington’s Disease

uniQure Provides Regulatory Update on AMT-130 for Huntington’s Disease LEXINGTON, Mass. and AMSTERDAM, Nov. 03, 2025 (GLOBE NEWSWIRE) -- N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that it received feedback from the U.S. Food and Drug Administration (FDA) during a recent pre-Biologics License Application (BLA) meeting regarding AMT-130, an investigational gene therapy for Huntington’s disease (HD).   Though final meeting minutes have not yet been received, based on the discussions at the m...

November 3, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch